Company news
Novocure Limited (NASDAQ:NVCR) news
Novocure Limited news releases on 6ix. Latest, Oct 1, 2026: Novocure to Report Third Quarter 2026 Financial Results
Press releases & updates
Novocure to Report Third Quarter 2026 Financial Results
September 30, 2026
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
September 30, 2026
Novocure to Report Third Quarter 2026 Financial Results
October 1, 2026
Novocure Reports Second Quarter 2026 Financial Results
July 23, 2026
Novocure to Report Second Quarter 2026 Financial Results
July 1, 2026
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
June 30, 2026
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
June 18, 2026
Novocure Reports First Quarter 2026 Financial Results
April 30, 2026
Novocure to Report First Quarter 2026 Financial Results
March 31, 2026
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
March 25, 2026
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
March 1, 2026
Novocure to Participate in 2026 Leerink Global Healthcare Conference
February 27, 2026
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
February 25, 2026
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
February 23, 2026
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
February 11, 2026
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
January 11, 2026
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
December 21, 2025
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
November 30, 2025
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
November 25, 2025
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
November 11, 2025
Novocure Reports Third Quarter 2025 Financial Results
October 29, 2025
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
October 14, 2025
Novocure to Report Third Quarter 2025 Financial Results
September 30, 2025
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
September 28, 2025
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
September 14, 2025
Novocure Announces Upcoming Investor Events
August 27, 2025
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
August 24, 2025
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
August 19, 2025
Novocure Reports Second Quarter 2025 Financial Results
July 23, 2025
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
June 30, 2025
Novocure to Report Second Quarter 2025 Financial Results
June 29, 2025
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
May 30, 2025
Novocure Reports First Quarter 2025 Financial Results
April 23, 2025
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
April 22, 2025
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
April 21, 2025
Novocure to Report First Quarter 2025 Financial Results
March 31, 2025
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
March 3, 2025
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
February 26, 2025
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
January 21, 2025
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
January 12, 2025
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
January 2, 2025
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
December 1, 2024
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
December 1, 2024
Novocure to Participate in Upcoming Investor Conferences
November 26, 2024
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
November 20, 2024
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
November 20, 2024
Novocure Reports Third Quarter 2024 Financial Results
October 29, 2024
Novocure Appoints Christoph Brackmann as Chief Financial Officer
October 29, 2024
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
October 14, 2024
Novocure to Report Third Quarter 2024 Financial Results
September 30, 2024